Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PAVmed Inc. SEC filings document its medical technology business, subsidiary operations and capital structure. Form 8-K reports cover operating results, business updates, Regulation FD disclosures, material agreements and Nasdaq listing-compliance matters for the company and its medical device, diagnostics and digital health activities.
Proxy statements and stockholder-meeting filings describe governance, voting matters and authorization of share issuances tied to preferred stock, warrants and convertible debt. Recent capital-structure disclosures include Series D Convertible Preferred Stock, warrants to purchase preferred stock, redemption of Series C Preferred Stock, and refinancing of a senior secured convertible note.
MCGRATH DENNIS M reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. reported that President and CFO Dennis M. McGrath received a grant of 180,000 shares of restricted common stock on April 2, 2026. The award was made under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
The restricted stock carries a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, McGrath directly holds 186,695 shares of PAVmed common stock.
Glennon Michael J reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Michael J. Glennon reported an award of 13,930 shares of restricted common stock as equity compensation. The shares were granted at no cash cost to him under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and have a single vesting date of May 20, 2029. The restricted stock is subject to forfeiture if he does not complete the required service period. Following this grant, Glennon directly holds 21,653 shares of PAVmed common stock.
Baxter Timothy E reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Timothy E. Baxter received a grant of 13,930 shares of restricted common stock as equity compensation. These shares vest on May 20, 2029 and may be forfeited if he does not complete the required service period. Following this award, he directly holds 21,097 common shares.
White Debra reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Debra White received a grant of 13,930 shares of restricted common stock as compensation. The award was granted at $0.00 per share under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if the required service period is not completed. Following this grant, White directly holds 21,097 shares of PAVmed common stock.
Sparks Ronald M reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Ronald M. Sparks received a grant of 13,930 shares of common stock as restricted stock under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan. The award has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Sparks directly holds 21,097 shares of PAVmed common stock.
Agrawal Sundeep reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. director Sundeep Agrawal received a grant of 13,930 shares of restricted Common Stock as equity compensation. The award was granted at no cash purchase price and increases his direct holdings to 19,337 shares after the transaction.
The restricted stock was issued under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if he does not complete the required service period, tying the award to long-term board service.
PAVmed Inc. reports that Tasso Partners, LLC and Dana Carrera beneficially own 912,996 and 914,246 shares respectively, representing 14.3% of outstanding common stock. The percentage is calculated using 6,383,089 shares outstanding as of March 27, 2026, per the annual report on Form 10-K.
The filing states Ms. Carrera controls Tasso Partners through Tasso Capital, LLC and that the Reporting Persons filed this Amendment No. 1 jointly under a Joint Filing Agreement.
Gordon Michael Adam reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. granted its General Counsel, Michael Adam Gordon, 110,000 shares of restricted common stock as equity compensation. The shares were granted at no cash cost and bring his direct holdings to 115,000 shares. The award vests on May 20, 2029 and is subject to forfeiture if he does not complete the required service period, making this a long-term retention incentive rather than an open-market purchase.
O'Neil Shaun reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. Chief Operating Officer Shaun O'Neil received a grant of 110,000 shares of common stock as restricted stock under the company's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan. The award has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, O'Neil directly holds 115,598 shares of PAVmed common stock.
PAVmed Inc. reported fourth quarter and full year 2025 results and detailed major balance sheet and business changes. For the three months ended December 31, 2025, revenue was $52,000, operating expenses were about $6.9 million, and GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per diluted share. Non-GAAP adjusted loss was about $0.9 million, or $(1.05) per share.
The company raised $30 million through a Series D preferred stock offering and $15 million via senior secured notes, using part of the proceeds to eliminate all previously outstanding convertible securities and extend its cash runway. It also issued $30 million in Series D warrants linked to a draft CMS coverage policy for Lucid’s EsoGuard test, reported cash and cash equivalents of $1.5 million as of December 31, 2025, and highlighted progress at subsidiaries Lucid Diagnostics and Veris Health, including a VA contract for EsoGuard, large real-world data on esophageal precancer detection, and advancement of an implantable physiological monitor toward a planned late 2026 FDA 510(k) submission.